CRSP Stock: Price, Earnings History and SEC Filings
CRISPR Therapeutics AG (CRSP) last traded at $51.42, down 5.23% on the latest session and down 7.0% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.94 against an analyst estimate of $-1.10, a beat of 14.5%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
CRSP earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 3, 2026 | $-0.94 | $-1.10 | +14.55% |
| Mar 2026 | May 4, 2026 | $-1.28 | $-1.14 | -12.28% |
| Dec 2025 | Feb 12, 2026 | $-1.37 | $-1.15 | -19.13% |
| Sep 2025 | Nov 10, 2025 | $-1.17 | $-1.32 | +11.36% |
CRSP beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How CRSP reacts to earnings
Across its last 8 earnings releases, CRSP moved 4.8% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-03 | After close | +7.06% |
| 2026-05-04 | After close | -2.24% |
| 2026-02-12 | After close | +8.46% |
| 2025-11-10 | Before open | -0.98% |
| 2025-08-04 | After close | -6.71% |
| 2025-05-06 | After close | +3.29% |
| 2025-02-11 | After close | +9.29% |
| 2024-11-05 | Before open | -0.45% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
CRSP financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $4M | -$582M | -$346M | -16569.8% | $-6.47 |
| 2024 | $37M | -$366M | -$145M | -981.5% | $-4.34 |
| 2023 | $371M | -$154M | -$270M | -41.4% | $-1.94 |
| 2022 | $1M | -$650M | -$533M | -54271.7% | $-8.36 |
| 2021 | $915M | $378M | $457M | 41.3% | $4.70 |
| 2020 | $719000 | -$349M | -$257M | -48520.9% | $-5.29 |
| 2019 | $290M | $67M | $50M | 23.1% | $1.17 |
| 2018 | $3M | -$165M | -$99M | -5281.1% | $-3.44 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for CRSP
- 8-K · Oct 19, 2026Officer or director change, Financial statements and exhibits
- 10-Q · Aug 3, 2026
- 8-K · Aug 3, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 4, 2026Officer or director change, Bylaw change, Shareholder vote
- 10-Q · May 4, 2026
- 8-K · May 4, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 21, 2026
- 8-K · Mar 16, 2026Material agreement, New financial obligation, Unregistered share sale
- 8-K · Mar 11, 2026Other events, Financial statements and exhibits
- 10-K · Feb 12, 2026
Insider filing activity
CRSP insiders filed 14 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
CRSP news
- Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader MarketOct 30, 2026 · finance.yahoo.com
- Fidelity’s Health Care ETF Holds the Biotechs XLV Skips. Retirees Should Know the DifferenceOct 30, 2026 · 247wallst.com
- 3 Promising Genomics Stocks to Add to Your Portfolio NowOct 30, 2026 · finance.yahoo.com
- Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?Oct 27, 2026 · finance.yahoo.com
- Learn Why The Bull Case For CRISPR Therapeutics Stock Could Change Following CFO ChangeOct 25, 2026 · finance.yahoo.com
- CRISPR Therapeutics (CRSP) Promotes Andrew Silver To CFO As Raju Prasad ResignsOct 25, 2026 · finance.yahoo.com
- Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter MoreOct 24, 2026 · fool.com
- CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should KnowOct 23, 2026 · finance.yahoo.com
About CRISPR Therapeutics AG
CRISPR Therapeutics AG (CRSP) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in Switzerland. Its fiscal year ends in December.